Results: SBTX

Search articles by EPIC code

SkinBioTherapeutics – interim numbers & warning of slight delay largely irrelevant, the clear potential remains - Buy

SkinBioTherapeutics (SBTX) has announced results for its half-year ended 31st December 2021 which show revenue of just £21,949, cash £1.5 million lower to £3.2 million and include a warning that full-year forecasts will be materially missed – and the shares have responded down to 35p. But here’s why we retain significant confidence and see this as a buying opportunity. From here this could be a 10 bagger.


SkinBioTherapeutics – OptiBiotix’s share sale, who does it think it’s kidding?

Having been falling from early this month, shares in SkinBioTherapeutics (SBTX) are currently further lower after it announced “OptiBiotix Health Plc has placed 3,636,363 ordinary shares in SkinBioTherapeutics with new and existing institutional investors at a price of 55 pence per share”. With SkinBioTherapeutics CEO Stuart Ashman though arguing “the company is going from strength to strength” and “it is important to attract new investors who are keen to come on board to support us in the next stage of the company's development, as a commercial entity”, why the further share price fall?


SkinBioTherapeutics – announces AxisBiotix-Ps launch date, high margin profit potential moving closer - we are 289% ahead but much more to come

As things stand at 69p, we are 289% ahead on this share tip but there is much more to come. SkinBioTherapeutics (SBTX) has announced its probiotic food supplement to help alleviate the symptoms of psoriasis, AxisBiotix-Ps, is to launch on 29th October, following highly positive results from its consumer study in May and key commercialisation activities since.

Page 1 of 5 (42 articles)
Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Complete Coverage

Recent Comments